Henry Schein, Inc. (NASDAQ:HSIC – Free Report) – Investment analysts at Barrington Research lowered their Q4 2024 earnings estimates for shares of Henry Schein in a research note issued on Wednesday, November 6th. Barrington Research analyst M. Petusky now anticipates that the company will post earnings of $1.20 per share for the quarter, down from their prior estimate of $1.27. Barrington Research currently has a “Outperform” rating and a $82.00 target price on the stock. The consensus estimate for Henry Schein’s current full-year earnings is $4.74 per share. Barrington Research also issued estimates for Henry Schein’s Q1 2025 earnings at $1.12 EPS, Q2 2025 earnings at $1.26 EPS, Q3 2025 earnings at $1.27 EPS, Q4 2025 earnings at $1.46 EPS, FY2025 earnings at $5.12 EPS and FY2026 earnings at $5.80 EPS.
A number of other equities analysts have also recently commented on HSIC. StockNews.com upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a research report on Thursday. Evercore ISI boosted their target price on Henry Schein from $70.00 to $74.00 and gave the company an “in-line” rating in a research note on Tuesday, October 8th. Baird R W upgraded Henry Schein from a “hold” rating to a “strong-buy” rating in a report on Monday, July 22nd. Robert W. Baird decreased their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. dropped their price objective on Henry Schein from $88.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Henry Schein has an average rating of “Hold” and a consensus price target of $77.50.
Henry Schein Trading Down 0.8 %
Shares of HSIC opened at $69.43 on Thursday. Henry Schein has a fifty-two week low of $62.12 and a fifty-two week high of $82.63. The firm has a market cap of $8.80 billion, a price-to-earnings ratio of 25.71, a PEG ratio of 2.08 and a beta of 0.87. The firm has a 50 day moving average price of $70.56 and a 200-day moving average price of $69.78. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.90 and a current ratio of 1.55.
Henry Schein (NASDAQ:HSIC – Get Free Report) last released its earnings results on Tuesday, November 5th. The company reported $1.22 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.05. Henry Schein had a return on equity of 13.19% and a net margin of 2.82%. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.24 billion. During the same quarter in the previous year, the company posted $1.32 EPS. Henry Schein’s quarterly revenue was up .4% compared to the same quarter last year.
Hedge Funds Weigh In On Henry Schein
Several institutional investors and hedge funds have recently added to or reduced their stakes in HSIC. Cromwell Holdings LLC increased its stake in shares of Henry Schein by 93.4% in the 3rd quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock worth $26,000 after acquiring an additional 170 shares in the last quarter. Summit Securities Group LLC purchased a new stake in Henry Schein in the second quarter worth about $31,000. Beach Investment Counsel Inc. PA bought a new position in shares of Henry Schein during the second quarter valued at approximately $37,000. Blue Trust Inc. lifted its holdings in shares of Henry Schein by 104.2% during the second quarter. Blue Trust Inc. now owns 931 shares of the company’s stock valued at $60,000 after purchasing an additional 475 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of Henry Schein by 58.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 933 shares of the company’s stock worth $68,000 after purchasing an additional 346 shares in the last quarter. Hedge funds and other institutional investors own 96.62% of the company’s stock.
Insider Buying and Selling
In other Henry Schein news, SVP Lorelei Mcglynn sold 21,035 shares of the firm’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the sale, the senior vice president now directly owns 71,833 shares in the company, valued at $4,978,026.90. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 1.14% of the stock is currently owned by insiders.
Henry Schein Company Profile
Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.
Recommended Stories
- Five stocks we like better than Henry Schein
- Compound Interest and Why It Matters When Investing
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- 3 Tickers Leading a Meme Stock Revival
- Breakout Alert: Qualcomm Just Hit The Rally Button
- Which Wall Street Analysts are the Most Accurate?
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.